EPE Special Opportunities Reports 10% NAV Growth and Portfolio Progress in FY2026

EPE Special Opportunities: 10% NAV Uplift, portfolio momentum, and a still-wide discount

EPE Special Opportunities (ESO) has posted a solid trading update for the year to 31 January 2026. The headline is a 10% rise in NAV per share to 360 pence, set against a share price of 150 pence. That leaves a chunky discount and, in my view, clear scope for value if portfolio progress keeps translating into numbers.

Under the bonnet, there is encouraging trading from several holdings, active capital management, and a cleaner balance sheet with healthy liquidity. There are also a few watchpoints – notably the upcoming conversation with ZDP holders and working capital needs at Denzel’s – but overall the tone is constructive.

Key numbers investors should know

NAV per share (31 Jan 2026)	360 pence (+10% year on year)
Share price (31 Jan 2026)	150 pence (+1% year on year)
Implied discount to NAV	c.58%
Cash balance	£14.1 million (see note below)
Ordinary share buybacks	1.8 million shares at 147 pence average
ZDP shares repurchased	1.5 million; 8.0 million remaining, maturing December 2026
Unsecured loan notes (ULN)	£4.0 million maturity extended to July 2026
Other third-party debt	None
Unquoted portfolio valuation	8.0x EBITDA-to-enterprise value multiple
Aggregate portfolio leverage	Net debt at 0.9x EBITDA

Quick jargon check: NAV is net asset value – effectively the per-share value of ESO’s assets less liabilities. ZDPs are zero dividend preference shares that do not pay income but redeem at a set date and value. ULN stands for unsecured loan notes (corporate debt). The cash figure includes cash held by subsidiaries where ESO is the sole investor.

Portfolio highlights: green shoots and some outperformance

Luceco: ahead of expectations with energy transition tailwinds

Luceco’s January update impressed. Revenue hit £271 million for 2025, up 12%, with EV charging sales up a punchy 85%. Adjusted operating profit is expected to be at least £33.5 million, c.15% growth, implying 12% margins that are above the upper end of market expectations. Adjusted free cash flow of about £30 million pulled net leverage down to 1.3x, comfortably inside the 1.0 – 2.0x target range.

Why it matters: momentum here helps ESO’s NAV resilience. Operational efficiencies, acquisition synergies and exposure to energy transition are attractive drivers, though we do not have ESO’s exact stake size disclosed.

Whittard of Chelsea: record EBITDA and strong UK retail

Whittard delivered its fifth straight year of sales growth and record EBITDA. UK stores were lively with 13% like-for-like growth and a string of new openings in Shaftesbury Avenue, Bluewater, Nottingham, Kingston and Manchester. Internationally, Whittard opened a 3PL hub in Hong Kong and grew franchises and wholesale.

On financing, Whittard secured a £10.0 million term loan and £2.0 million revolving credit facility in August 2025. The term loan repaid ESO 1 shareholder loans, with the proceeds flowing back to ESO. That boosts ESO liquidity and reduces look-through concentration risk.

Rayware and LSA International: integration completed, synergies landing

ESO 1 acquired premium glassware brand LSA International in July 2025 and integrated it into The Rayware Group by early February 2026. Management flags increased scale and improved profitability via revenue and cost synergies. Rayware also saw improving sales momentum, led by the US and marketplace channels.

Positive read-across: consolidation within the homewares platform offers multiple levers – cross-selling, procurement, and distribution – though precise synergy figures are not disclosed.

Pharmacy2U: Online Doctor scaling, eScript steady

Pharmacy2U accelerated growth. The Services division, driven by Online Doctor, scaled materially, while the eScript business continued to grow following the LloydsDirect integration. No financials were disclosed, but the direction of travel is encouraging in what remains a competitive digital healthcare space.

Denzel’s: strategy sharpened, funding under review

Denzel’s pivoted to focus on key retail accounts and marketplace channels and appointed a COO. ESO 1 invested an additional £0.4 million in March 2025. The company is reviewing working capital needs to deliver its medium-term plan. That is sensible housekeeping but does flag potential for further support if required.

Capital management: buybacks, liquidity, and a ZDP decision ahead

ESO leaned into capital discipline. Ordinary share buybacks of 1.8 million shares at 147 pence signal confidence and are earnings-accretive at a wide discount. The company also repurchased 1.5 million ZDPs, leaving 8.0 million in issue and a December 2026 maturity. Management will engage with ZDP holders on a potential extension to the redemption date.

On the liability side, £4.0 million of unsecured loan notes have been rolled to July 2026, and there is no other third-party debt. Cash of £14.1 million provides optionality for follow-ons and portfolio support. The upcoming ZDP discussion is the key near-term capital structure event; a smooth extension would be a clear de-risker, while tougher terms would not be surprising given the rate backdrop.

Valuation context: wide discount meets improving fundamentals

The shares closed January at 150 pence versus a 360 pence NAV – roughly a 58% discount. That is wide against a portfolio that, on ESO’s methodology, is valued at an 8.0x EBITDA-to-enterprise value multiple and carries modest aggregate leverage of 0.9x EBITDA. If trading momentum at Luceco, Whittard, Rayware/LSA and P2U continues, there is a reasonable case for discount narrowing.

The other side of the ledger: macro remains “complex” in the company’s words, consumer-facing names are not out of the woods, Denzel’s may need more working capital, and the ZDP extension outcome is not guaranteed. These are manageable, but they matter for timing.

Chair’s view and my take

Chairman Clive Spears summed it up: “Although the operating environment during the period has remained challenging, the Board and Investment Advisor have continued to progress the development of the portfolio and the prudent management of liquidity.” That chimes with the evidence in this update.

My read: this is a good step in the right direction. NAV is up 10%, multiple portfolio assets are executing, liquidity is healthy, and the balance sheet is simple. The discount remains the glaring opportunity – and the glaring question. Delivery on trading, visible LSA synergies, and a tidy ZDP solution would all help unlock it.

What to watch next

• ZDP engagement outcome – terms and timing of any extension.
• Further detail on LSA synergy capture within Rayware.
• Whittard’s international expansion run-rate post Hong Kong 3PL hub.
• Pharmacy2U financials to back the growth narrative.
• Denzel’s working capital plan and trading traction in key retail accounts.

Overall, an encouraging update from ESO with tangible portfolio progress and sensible capital moves. If the momentum holds, the current discount could start to look overly harsh.